IMUNON

We are dedicated to transforming care for women facing advanced ovarian #cancer. Additional insights from our Phase 2 OVATION 2 study highlight the potential of our proprietary TheraPlas® technology to address the urgent need for new treatment options. With plans underway to initiate a Phase 3 pivotal clinical trial in early 2025, we remain focused on advancing innovation to make a meaningful difference for patients and their families. Read more in our press release: https://lnkd.in/e4M6uvgA

DNA is the fundamental building block of life, coding for the proteins that shape our bodies. At IMUNON, we’re pioneering DNA as a therapeutic agent, taking this concept further by exploring DNA’s potential to code for proteins that enable the body to produce its own medicine precisely where and when it’s needed. This approach has the potential to transform treatment options by empowering patients’ own immune systems for healing. Discover our pipeline of DNA-based therapies: https://lnkd.in/esFAadBW #InnovativeTherapies #OvarianCancerAwareness #CancerResearch #Immunotherapy #WomensHealth

At IMUNON, collaboration is at the core of our mission. That’s why we’re dedicated to partnering with key organizations that share our vision of developing new medicines to better serve patients with difficult-to-treat conditions, including #ovariancancer. If you’re interested in learning more about our partnerships or exploring collaboration opportunities, we’d love to connect! Together, we can drive transformative breakthroughs in #oncology treatment and care. Learn more at https://lnkd.in/eYW7Rs4B #InnovativeTherapies #OvarianCancerAwareness #CancerResearch #Immunotherapy #WomensHealth

#ICYMI, our CEO Dr. Stacy Lindborg and gynecologic oncologist Dr. Premal Thaker recently shared their perspectives on the OVATION 2 study and its implications for ovarian cancer treatment in an interview with ONCOLife. They discussed the use of our innovative therapy alongside other treatments for newly diagnosed patients, highlighting the potential of our technology to strengthen anticancer immunity. Their conversation also touched on promising study findings and the next steps in our clinical development pathway, as we explore applications across additional cancer types. For more insights, watch the full interview: https://lnkd.in/dQ6y_NvA #InnovativeTherapies #OvarianCancerAwareness #CancerResearch #Immunotherapy #WomensHealth

Happy Thanksgiving from our team at IMUNON to yours! As we take this time to reflect, we are truly thankful for the unwavering support of our dedicated team, valued partners and the inspiring #ovarian cancer community. Together, we are making meaningful strides in the fight against cancer. #HappyThanksgiving #OvarianCancerAwareness #CancerResearch #Immunotherapy #WomensHealth

We recently concluded a productive in-person End-of-Phase 2 meeting with the FDA, receiving support for a proposed Phase 3 trial design for our lead #immunotherapy program in advanced ovarian cancer. This milestone reflects our collaborative efforts to address a significant unmet need in ovarian cancer treatment. With the final protocol submission on track for December, we are preparing to initiate a Phase 3 registrational trial in Q1 2025. Learn more about our progress in advancing treatment options for women with advanced ovarian cancer: https://lnkd.in/e3S7RK3G

At IMUNON, we recognize the critical role that family caregivers play in the lives of those facing difficult-to-treat cancers, including #ovarian cancer. This National Family Caregivers Month (#NFCM), we’re committed to raising awareness of the unique challenges caregivers face, celebrating their invaluable contributions, and advocating for the resources and support they need. Join us in honoring caregivers by listening to their stories and exploring ways to support them on their journey. Together, we can make a meaningful impact on the lives of caregivers and those they care for. Learn more from Caregiver Action Network: https://lnkd.in/e9V3RjGn

Last week at #SITC2024, our team presented new clinical data from our OVATION 2 study of our investigational therapy for advanced ovarian cancer in a late-breaking session. These findings underscore our commitment to advancing innovative therapies for those facing this challenging disease as we look ahead to an End-of-Phase 2 meeting with the FDA and prepare for a pivotal Phase 3 study. Thanks to The Society for Immunotherapy of Cancer (SITC) for a successful event! The insights shared were invaluable, and we look forward to building on these discussions as we work to advance innovative options in #cancer treatment. To access our poster presentation, visit: https://lnkd.in/eH6BFaRt

In this interview with ONCOLife, our CEO Dr. Stacy Lindborg and leading gynecologic oncologist Dr. Premal Thaker engage in a thought-provoking discussion on #immunotherapy and recent advances in ovarian #cancer research, including key findings from the OVATION 2 study. They also explore how our therapy could offer potential advantages over the current standard of care and address the critical needs of those impacted by #ovariancancer. Read the full interview here: https://lnkd.in/dsf-G_YF #OvarianCancerAwareness #CancerResearch #Immunotherapy #WomensHealth

Today our team will present a late-breaking poster at The Society for Immunotherapy of Cancer (SITC)’s Annual Meeting, featuring new clinical data from the Phase 2 OVATION 2 study and our investigational therapy for the treatment of advanced ovarian cancer. We look forward to sharing additional data from the OVATION 2 study with the oncology and immunotherapy community as we work towards making a meaningful impact in ovarian cancer treatment. For details: https://lnkd.in/eVgP_eUW #SITC2024 #InnovativeTherapies #OvarianCancerAwareness #CancerResearch #Immunotherapy #WomensHealth